Table 2 Details of treatment
Characteristics | All (n = 37) | Group A (n = 10) | Group B (n = 9) | Group C (n = 18) | |
|---|---|---|---|---|---|
Total dose (Gy, RBE) | Median (range) | 70 (50-81.4) | 66 (50–74) | 70 (70–78) | 74 (70-81.4) |
Concurrent chemotherapy | Cisplatin | 11 | 2 | 3 | 6 |
S-1 | 7 | 0 | 4 | 3 | |
5-FU, cisplatin | 4 | 0 | 1 | 3 | |
None | 15 | 8 | 1 | 6 | |
Induction chemotherapy | Docetaxel, cisplatin, 5-FU | 3 | 2 | 0 | 1 |
5-FU, cisplatin | 1 | 0 | 0 | 1 | |
None | 33 | 8 | 9 | 16 | |
Surgery | Extensive skull base tumor resection, dural resection and reconstruction | 5 | 5 | 0 | 0 |
Endoscopic nasal tumor resection | 3 | 3 | 0 | 0 | |
Total maxillary resection | 2 | 2 | 0 | 0 | |
Biopsy only | 27 | 0 | 9 | 18 | |